MedWatch

Solomon has Danish ambitions for Norwegian company

Interview: David Solomon will leave Zealand Pharma in a few days, but the Canadian national is not leaving Denmark, although he is becoming the CEO of a public, Norwegian biotech company. He loves the Danish eco system, so this is where his new company should flourish as well, he says.

Foto: Zealand Pharma/PR

“I will be back in an executive role,” David Solomon told MedWatch in November when Zealand Pharma announced he would be stepping back from the company from January 15th – and this weekend he made good on that promise.

The Norway-based biotech company Bionor Pharma announced that David Solomon would take over as CEO of the company, which boasts a market cap of USD 77.5 million against Zealand’s market cap of USD 339 million.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP blåstempler ni nye lægemidler i maj

Den europæiske lægemiddelkomite, CHMP, har på dets møde i maj indstillet ni nye lægemidler til godkendelse samt anbefalet, at seks midler kan tages i brug på nye måder. To midler afvist.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier